Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

2,573 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.
Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, Heilig CM, Bernardo J, Choudhri S, Grosset JH, Guy E, Guyadeen P, Leus MC, Maltas G, Menzies D, Nuermberger EL, Villarino M, Vernon A, Chaisson RE; Tuberculosis Trials Consortium. Dorman SE, et al. Among authors: Goldberg S. Am J Respir Crit Care Med. 2009 Aug 1;180(3):273-80. doi: 10.1164/rccm.200901-0078OC. Epub 2009 Apr 30. Am J Respir Crit Care Med. 2009. PMID: 19406981 Clinical Trial.
Geographic differences in time to culture conversion in liquid media: Tuberculosis Trials Consortium study 28. Culture conversion is delayed in Africa.
Mac Kenzie WR, Heilig CM, Bozeman L, Johnson JL, Muzanye G, Dunbar D, Jost KC Jr, Diem L, Metchock B, Eisenach K, Dorman S, Goldberg S. Mac Kenzie WR, et al. Among authors: Goldberg S. PLoS One. 2011 Apr 11;6(4):e18358. doi: 10.1371/journal.pone.0018358. PLoS One. 2011. PMID: 21494548 Free PMC article. Clinical Trial.
Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin.
Weiner M, Burman W, Luo CC, Peloquin CA, Engle M, Goldberg S, Agarwal V, Vernon A. Weiner M, et al. Among authors: Goldberg S. Antimicrob Agents Chemother. 2007 Aug;51(8):2861-6. doi: 10.1128/AAC.01621-06. Epub 2007 May 21. Antimicrob Agents Chemother. 2007. PMID: 17517835 Free PMC article. Clinical Trial.
Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium.
Dorman SE, Goldberg S, Stout JE, Muzanyi G, Johnson JL, Weiner M, Bozeman L, Heilig CM, Feng PJ, Moro R, Narita M, Nahid P, Ray S, Bates E, Haile B, Nuermberger EL, Vernon A, Schluger NW; Tuberculosis Trials Consortium. Dorman SE, et al. Among authors: Goldberg S. J Infect Dis. 2012 Oct 1;206(7):1030-40. doi: 10.1093/infdis/jis461. Epub 2012 Jul 30. J Infect Dis. 2012. PMID: 22850121 Clinical Trial.
Evaluation of time to detection of Mycobacterium tuberculosis in broth culture as a determinant for end points in treatment trials.
Weiner M, Prihoda TJ, Burman W, Johnson JL, Goldberg S, Padayatchi N, Duran P, Engle M, Muzanye G, Mugerwa RD, Sturm AW. Weiner M, et al. Among authors: Goldberg S. J Clin Microbiol. 2010 Dec;48(12):4370-6. doi: 10.1128/JCM.00757-10. Epub 2010 Oct 6. J Clin Microbiol. 2010. PMID: 20926712 Free PMC article.
Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis.
Burman WJ, Goldberg S, Johnson JL, Muzanye G, Engle M, Mosher AW, Choudhri S, Daley CL, Munsiff SS, Zhao Z, Vernon A, Chaisson RE. Burman WJ, et al. Among authors: Goldberg S. Am J Respir Crit Care Med. 2006 Aug 1;174(3):331-8. doi: 10.1164/rccm.200603-360OC. Epub 2006 May 4. Am J Respir Crit Care Med. 2006. PMID: 16675781 Clinical Trial.
Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy.
Weiner M, Bock N, Peloquin CA, Burman WJ, Khan A, Vernon A, Zhao Z, Weis S, Sterling TR, Hayden K, Goldberg S; Tuberculosis Trials Consortium. Weiner M, et al. Among authors: Goldberg S. Am J Respir Crit Care Med. 2004 Jun 1;169(11):1191-7. doi: 10.1164/rccm.200311-1612OC. Epub 2004 Feb 12. Am J Respir Crit Care Med. 2004. PMID: 14962821 Clinical Trial.
The scope and impact of treatment of latent tuberculosis infection in the United States and Canada.
Sterling TR, Bethel J, Goldberg S, Weinfurter P, Yun L, Horsburgh CR; Tuberculosis Epidemiologic Studies Cosortium. Sterling TR, et al. Among authors: Goldberg S. Am J Respir Crit Care Med. 2006 Apr 15;173(8):927-31. doi: 10.1164/rccm.200510-1563OC. Epub 2006 Jan 19. Am J Respir Crit Care Med. 2006. PMID: 16424442 Clinical Trial.
Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.
Dorman SE, Savic RM, Goldberg S, Stout JE, Schluger N, Muzanyi G, Johnson JL, Nahid P, Hecker EJ, Heilig CM, Bozeman L, Feng PJ, Moro RN, MacKenzie W, Dooley KE, Nuermberger EL, Vernon A, Weiner M; Tuberculosis Trials Consortium. Dorman SE, et al. Among authors: Goldberg S. Am J Respir Crit Care Med. 2015 Feb 1;191(3):333-43. doi: 10.1164/rccm.201410-1843OC. Am J Respir Crit Care Med. 2015. PMID: 25489785 Free PMC article. Clinical Trial.
Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection.
Borisov AS, Bamrah Morris S, Njie GJ, Winston CA, Burton D, Goldberg S, Yelk Woodruff R, Allen L, LoBue P, Vernon A. Borisov AS, et al. Among authors: Goldberg S. MMWR Morb Mortal Wkly Rep. 2018 Jun 29;67(25):723-726. doi: 10.15585/mmwr.mm6725a5. MMWR Morb Mortal Wkly Rep. 2018. PMID: 29953429 Free PMC article.
2,573 results
Jump to page
Feedback